Repligen Corporation (RGEN), a global bioprocessing company that develops technologies and consumables used in the manufacture of biologic drugs, saw its shares move sharply lower on Tuesday. The stock traded down approximately 4.13% to about $172.73, compared with a prior-session close of $180.17. The decline followed the company's third-quarter 2026 earnings release, in which a top-and-bottom-line beat was eclipsed by a GAAP operating loss and softer performance in its filtration franchise.
Repligen (RGEN) reported record third-quarter revenue of $209.3 million, up 11% as reported and 12.5% on an organic basis, driven by strength across its chromatography, proteins, and process analytics franchises. Adjusted earnings per share of $0.53 came in well ahead of the $0.46 consensus, and adjusted EBITDA of $43.8 million also exceeded expectations.
However, the company's GAAP results told a different story. Repligen (RGEN) posted a loss from operations of $29.5 million for the quarter, largely attributable to an intangible-asset impairment charge, and a GAAP loss per share of $0.68, compared with earnings of $0.26 per share a year earlier. The divergence between adjusted and GAAP figures weighed on sentiment, as investors recalibrated expectations around the company's reported profitability.
Beyond the headline numbers, markets focused on softness in the company's filtration segment, which posted a low double-digit decline on headwinds from the Polymem divestiture, foreign currency effects, and customer-specific challenges. Adjusted gross margin edged down roughly 30 basis points year over year to about 53%, reflecting an unfavorable product mix even as operating discipline lifted adjusted operating margin.
The combination of filtration softness and margin pressure suggested to some investors that growth remains uneven across the portfolio, tempering enthusiasm for what was otherwise a strong quarter in chromatography and proteins.
Management raised full-year 2026 revenue guidance to a range of $844 million to $852 million, implying reported growth of 14.5% to 15.5%, and lifted its adjusted EPS outlook to a midpoint of about $2.07. The company also highlighted the October closing of its BioLife Solutions acquisition, which it expects to strengthen its position in the high-growth cell therapy market.
Despite the constructive guidance and the strategic rationale for the deal, the stock's reaction reflected a "show-me" stance among investors, who appeared more focused on near-term execution and the impact of the impairment charge than on the longer-term growth narrative.
The decline in RGEN shares was earnings-driven rather than reflective of broad market weakness, as the move diverged from the broader bioprocessing and healthcare complex. The stock had been a strong performer over the prior three months, gaining more than 25%, which may have left it vulnerable to profit-taking once the quarterly report failed to deliver a clean, all-around beat. Traders are now watching whether the shares can hold key technical support after surrendering the gains that had built up heading into the report.
Looking ahead, investors will monitor the integration of BioLife Solutions, the durability of chromatography and proteins momentum, and any stabilization in the filtration segment. The company's raised guidance signals confidence in end-market demand, but execution against those targets will be closely scrutinized. Risks include continued filtration softness, gross margin fluctuations tied to product mix, and the potential for further impairment or integration costs. The market's next catalyst will likely be management's commentary on fourth-quarter trends and the early contribution from BioLife.
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-driven trading bots that cover thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots section to see which automated strategies are currently outperforming and to find ideas aligned with your own trading approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for RGEN crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 41 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
RGEN moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 70 cases where RGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +6.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.636) is normal, around the industry mean (4.964). RGEN has a moderately high P/E Ratio (234.446) as compared to the industry average of (40.591). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biologic drugs
Industry PharmaceuticalsOther